145 related articles for article (PubMed ID: 2610170)
21. Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma.
Richter EN; Oevermann K; Buentig N; Storkel S; Dallmann I; Atzpodien J
J Urol; 2002 Aug; 168(2):460-4. PubMed ID: 12131288
[TBL] [Abstract][Full Text] [Related]
22. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.
Horiguchi A; Oya M; Shimada T; Uchida A; Marumo K; Murai M
J Urol; 2002 Aug; 168(2):762-5. PubMed ID: 12131365
[TBL] [Abstract][Full Text] [Related]
23. Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma.
Lee SE; Byun SS; Oh JK; Lee SC; Chang IH; Choe G; Hong SK
J Urol; 2006 Oct; 176(4 Pt 1):1332-7; discussion 1337-8. PubMed ID: 16952624
[TBL] [Abstract][Full Text] [Related]
24. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
25. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma.
Obara W; Konda R; Akasaka S; Nakamura S; Sugawara A; Fujioka T
J Urol; 2007 Oct; 178(4 Pt 1):1497-503. PubMed ID: 17707062
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
[TBL] [Abstract][Full Text] [Related]
28. Outcomes following partial nephrectomy by tumor size.
Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
[TBL] [Abstract][Full Text] [Related]
29. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
30. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
31. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.
Tanioka F; Hiroi M; Yamane T; Hara H
Zentralbl Pathol; 1993 Aug; 139(3):185-93. PubMed ID: 8105885
[TBL] [Abstract][Full Text] [Related]
32. Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma.
Igarashi T; Murakami S; Isaka S; Okano T; Shimazaki J; Matsuzaki O
Eur Urol; 1991; 19(4):332-5. PubMed ID: 1915542
[TBL] [Abstract][Full Text] [Related]
33. [Serum levels of immunosuppressive acidic protein (IAP) in various disease states and their clinical significance].
Kikuchi S
Nihon Geka Gakkai Zasshi; 1984 Apr; 85(4):283-99. PubMed ID: 6749105
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas.
Castrén JP; Kamel DE; Nurmi MJ; Collan YU
Anticancer Res; 2000; 20(1B):537-40. PubMed ID: 10769721
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study on incidental renal cell carcinoma].
Yamaguchi K; Tominaga T; Nishimura Y
Hinyokika Kiyo; 1995 Feb; 41(2):93-9. PubMed ID: 7702013
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
37. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
38. [A study of an immunosuppressive acidic protein (IAP) in patients with a bone tumor].
Mori O; Yonemura K; Morisawa K
Gan No Rinsho; 1988 Oct; 34(12):1690-2. PubMed ID: 3193614
[TBL] [Abstract][Full Text] [Related]
39. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
[TBL] [Abstract][Full Text] [Related]
40. Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate.
Permpongkosol S; Bagga HS; Romero FR; Sroka M; Jarrett TW; Kavoussi LR
J Urol; 2006 Nov; 176(5):1984-8; discussion 1988-9. PubMed ID: 17070227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
